CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these types of B-cell lymphoma that has come back or hasn't responded to treatment: mantle cell lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or Waldenström macroglobulinemia.
- Your lymphoma cells must have a protein called BAFF-R on them (a lab test can confirm this).
- You have tried at least two prior treatments, including specific ones like anti-CD20 therapy or BTK inhibitors, and your cancer has gotten worse or come back.
- You have at least one tumor that is 1.5 centimeters or larger, or lymphoma in your bone marrow.
- You are between 18 and 75 years old and your overall health (liver, kidney, heart) is good enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.